

LEARNING OBJECTIVES

After this program, participants will be able to:

Implement guideline-based outcome reducing treatments in patients with T2D and CKD	Safely monitor and manage changes in potassium associated with new therapies	Identify the roles of different healthcare professionals in managing patients with T2D and CKD
	SPEAKER Dr. Michael Wang Nephrologist Grand River Nephrology	SPEAKER Dr. Phoebe Bishara Endocrinologist Kitchener, ON
	DATE April 18, 2023 TIME 6:30-8:30pm	
Agenda 6:30-7:00pm – Arrivals/Reception 7:00-8:00pm – Presentation 8:00-8:30pm – Q&A	Jan 677	Cation et Lynn's Bistro Belmont Avenue West chener, Ontario

Virtual option is also available - please register and a link will be sent in advance

Please RSVP at your earliest convenience to Rebecca Roberts <u>rebecca.roberts@bayer.com</u> or 705-443-9073

EXPERT STEERING COMMITTEE



Chair

Louis Girard, MD, MBT, FRCPC

Nephrologist and Clinical Associate Professor Medical Director of Glomerulonephritis Medical Director of Apheresis Department of Medicine, Division of Nephrology Cumming School of Medicine, University of Calgary Calgary, AB



Alice Y.Y. Cheng, MD FRCPC

Endocrinologist Trillium Health Partners & Unity Health Toronto Associate Professor, University of Toronto Toronto, ON



Ronald Goldenberg, MD, FRCPC, FACE Endocrinologist LMC Diabetes & Endocrinology

LMC Diabetes & Endocrinolog Concord, ON



Daniel Ngui, BScPT, PT, MD, CCFP, FCFP Clinical Professor, Department of Family Medicine University of British Columbia Medical Director, Fraser Street Medical Vancouver, BC



Elissa Weinberg, мD, ссFP, FCFP Family Physician Toronto, ON



Claudio Rigatto, мр, FRCPC, Msc Associate Professor, University of Manitoba Academic Director and Scientist Chronic Disease Innovation Centre Nephrologist, Manitoba Renal Program Winnipeg, MB



Rita Suri, MD, MSc, FRCPC

Director, Division of Nephrology Associate Professor of Medicine Catherine McLaughlin Hakim Chair in Medicine McGill University Montreal, QC